AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery ...Middle East

PR Newswire - News
SHANGHAI, April 12, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that DEXTENZA has been approved in Macau,...

Hence then, the article about affamed therapeutics announces new drug approval for dextenza in macau for the treatment of ocular inflammation and pain following ophthalmic surgery was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News